- Original article
- Open Access
Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia
AMB Express volume 9, Article number: 108 (2019)
Due to its potent cytotoxicity in BRCA-mutated tumors, synthetic lethality elicited by poly (ADP-ribose) polymerase (PARP) inhibitor gives renewed enthusiasm to researching and developing anti-cancer therapies. Chronic myeloid leukemia (CML) is a type of cancers that starts in certain blood-forming cells of the bone marrow. Here, we showed that poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib could induce a concentration-dependent cytotoxicity in CML cells derived from pediatric patients. During talazoparib treatment, autophagy was markedly activated, which was confirmed by the accumulation of autophagosomes, decrease of SQSTM1 and up-regulation of LC3-II. Inhibition of autophagy by pharmaceutical inhibitor chloroquine or small-interfering RNA siATG5 significantly increased the cytotoxicity of talazoparib in pediatric CML cells and elicited synergistic anti-tumor effect in patient-derived xenograft model. Our data demonstrated that autophagy played a cyto-protective role in talazoparib-treated pediatric CML and co-treatment with talazoparib and autophagy inhibitor could induce synergetic anti-tumor effect, providing novel insights for pediatric CML treatment.
Poly (ADP-ribose) polymerases (PARP) played critical roles in a variety of DNA repair processes through sensing single-strand breaks and regulating the subsequent base-excision repair (Fenerty et al. 2018; Karzai et al. 2018). Blocking PARP leads to the accumulation of single-strand breaks, which will activate homologous recombination repair (Ashworth 2008; Rouleau et al. 2010). BRCA1/2 are the critical proteins in homologous recombination and the mutation of BRAC1/2 in tumors may lead to defects in DNA repair (Farmer et al. 2005). Since researchers found that BRAC1/2-mutant tumors were sensitive to PARP inhibition a decade ago, several PARP inhibitors olaparib, rucaparib, niraparib and talazoparib have been approved by FDA to treat germline BRCA-mutated advanced ovarian cancer and breast cancer (Sun et al. 2017; Zimmer et al. 2018). However, indications for PARP inhibitors represent only a small fraction of cancers that carrying BRCA mutation. Chronic myeloid leukemia (CML) is a type of leukemia characterized by the abnormal accumulation of myeloid cells and CML in childhood accounts for 10% of all cases (Tang et al. 2018; Ureshino et al. 2018). Here, in this article we investigated the anti-tumor effect of PARP inhibitor talazoparib in pediatric CML and the underlying mechanisms.
Similar to nearly all contemporary therapies for patients with malignance, efficacy decreases with successive lines of treatment (Hartley et al. 2018; Johnson et al. 2011). Autophagy is an evolutionarily conserved cellular process, which plays an important role in tumor microenvironment (Zhang et al. 2018b). Many anti-tumor agents, including asparaginase, arginase, cisplatin and immune checkpoint inhibitor, activated autophagy in cancer cells (Chen et al. 2017; Shen et al. 2017; Zhang et al. 2018a). Blocking autophagy significantly increased the anti-tumor effect of these agents, demonstrating that autophagy could be an efficient target to enhance the efficacy of anti-tumor regents. Increasing studies demonstrated that autophagy was involved in DNA damage repair especially in tumor cells (Karantza-Wadsworth et al. 2007; Liu et al. 2015). Inhibition of autophagy degraded checkpoint kinase 1 and further diminished DNA damage repair. Defective autophagy by allelic loss of beclin 1 increased DNA damage and genomic instability in breast cancer (Karantza-Wadsworth et al. 2007). Herein, we hypothesized that autophagy was triggered in PARP inhibitor-treated pediatric CML cells and combining used of talazoparib and autophagy inhibitor could elicit synergetic anti-tumor effect in pediatric CML.
In this study, first we investigated the cytotoxicity of talazoparib in CML cells derived from pediatric patients. Then autophagy was determined in talazoparib-treated CML cells. Finally, we confirmed the role of autophagy by pharmaceutical inhibitor and small-interfering RNA (siRNA) in vitro and in vivo. Our data showed that talazoparib could reduce the cell viability of CML cells and co-treatment with talazoparib and autophagy could induce synergetic anti-tumor effect, providing novel strategy for pediatric CML patients.
Materials and methods
Talazoparib and autophagy inhibitor chloroquine were ordered from Selleck (Shanghai, China). CCK-8 kit was purchased from Beyotime Biotechnology (Haimen, China). Hoechst 33342 and Cyto-ID green were obtained from ENZO Life Science (Farmingclale, NY, USA). The primary antibodies anti-SQSTM1, anti-LC3-I/II and anti-β-actin were obtained from Cell Signaling Technology (Danvers, MA, USA). HRP-conjugated goat anti-mouse/rabbit IgG were obtained from MR Biotech (Shanghai, China).
Leukemic cells (P#1 and P#2) were purified by Ficoll-Hypaque (Sigma-Aldrich, USA) from peripheral blood of two 12-years-old pediatric CML patients presenting with typical immunophenotype and morphology. CML cells were cultured in RPMI-1640 containing 10% FBS (Gibco, USA) at 37 °C in a humidified atmosphere of 5% CO2 incubator.
CCK-8 assay was used to measure cell viability. Briefly, CML (P#1 and P#2) cells were seeded into 96-well plates in a concentration of 5 × 104 cells/mL. After treatment with talazoparib and/or autophagy inhibitor at indicated concentrations, CCK-8 was added to each well for 4 h at 37 °C. Then the optical density value was detected by a UV spectrophotometry at 450 nm.
Transmission electron microscopy
CML cells were treated with talazoparib for 48 h. Then the samples were harvested and processed under the instructions (Shenoy et al. 2018). A transmission electron microscope (TEM, JEM 1410) was used to detect the sliced samples. Micrographs were obtained at the magnification of 7000× or 20,000×.
After treatment with various concentration of talazoparib and/or autophagy inhibitors for 48 h, CML cells were subjected to protein extracted extraction and equivalent amounts of the extraction were separated by SDS-PAGE and transferred onto PVDF membranes. Following blockage of nonspecific sites with 5% bovine saline albumin, the membranes were incubated with primary antibodies and subsequently subjected to secondary antibodies. ImageJ Software was used to quantify the resulting bands.
CML cells were treated with talazoparib for 48 h and rapamycin was employed as a positive control. Then, cells were incubated with Cyto-ID and Hoechst 33342 following the manufacturer’s instructions (Samaniego et al. 2018). Subsequently, a confocal microscopy (Carl Zeiss LSM710, Carl Zeiss, Germany) was employed to observe the cells.
Human ATG5 siRNA and non-silencing scrambled control (SCR) siRNA were obtained from Sangon Biotech (Shanghai, China). Cells were transfected with 50 nM of siRNA and Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen, USA) for 24 h. Then the cells were collected and the expression level of ATG5 was detected to the transfection efficiency.
Patient-derived xenograft (PDX) model
Male BALB/c nude mice (6 weeks) were subcutaneously injected with 1 × 107 of patient-derived cells (P#1) suspended in 50% Martigel Matrix (Corning, USA) to establish CML patient-derived xenograft model (Hu et al. 2018). Treatment was started once the volume of the tumor reached approximately 100 mm3 (volume = length × width × width/2). Mice were randomized into four cohorts as indicated. Talazoparib (50 mg/kg) was administrated orally once a day and chloroquine (50 mg/kg) was intraperitoneally injected once a day. Tumor volume was measured once every 3 days.
Results were shown as mean ± SD and comparisons were performed using Student’s t-test. Value of P < 0.05 was considered statistically significant.
PARP inhibition induced cytotoxicity in CML cells
As PARP is involved in DNA repair and over-expressed in various cancers, inhibitors targeting PARP have gained huge success in clinic (LaFargue et al. 2019). In this study, first we investigated whether inhibition of PARP by talazoparib could induce cytotoxicity in primary CML P#1 and P#2 cells in vitro. The cell viability of CML cells in response to various concentrations of talazoparib was measured by CCK-8 assay. As shown in Fig. 1, treatment with talazoparib for 48 h decreased the cell growth ability of CML in a dose-dependent manner. Moreover, a significant decrease of cell viability was observed in CML cells incubated with 20 μM talazoparib.
PARP inhibitor talazoparib triggered autophagy in CML cells
Increasing literatures showed that autophagy was involved and played critical role in cancer therapy (Zhang et al. 2017). Hence, we tried to investigate whether autophagy was involved in CML cells treated with talazoparib. First, ultrastructural analysis by TEM was applied to determine the hallmark of autophagy, autophagosomes, which was characterized by double-membraned vesicles. After talazoparib administration for 48 h, CML P#1 cells showed a significant accumulation of autophagosomes in the cytoplasm (Fig. 2a). Similar result was also observed in the cytoplasm of CML P#2 cells (Fig. 2b). These data demonstrated that autophagy was initiated in human CML cells after talazoparib treatment. Then, immunoblot analysis was used to detect the level of two autophagy-related protein, sequestosome 1 (SQSTM1) and microtubule-associated protein 1 light chain3 (LC3). Figure 3 showed that talazoparib obviously increased the level of LC3-II and reduced the level of SQSTM1 in CML cells in a concentration-dependent manner after talazoparib treatment. Furthermore, Cyto-ID, an autophagic vesicle-specific dye was employed to confirm talazoparib-induced autophagy in CML cells. Similar to the positive control rapamycin-treated cells, cells exposure to talazoparib increased the punctate fluorescence in the cytoplasm. In summary, these results showed that PARP inhibitor talazoparib activated autophagy in CML cells (Fig. 4).
Autophagy inhibition potentiated the cytotoxicity of talazoparib in CML cells
To investigate the effect of autophagy in talazoparib-induced cytotoxicity in CML cells, chloroquine, a classic autophagy inhibitor was used to block talazoparib-triggered autophagy. Immunoblot analysis showed that the level of LC3-II in the cells treated with talazoparib and chloroquine was obviously increased than that in talazoparib-treated cells, indicating that talazoparib-induced autophagy was successfully blocked by chloroquine (Fig. 5). Chloroquine did not induced significant cytotoxicity in CML P#1 and P#2 cells. Meanwhile, talazoparib in combination with chloroquine significantly potentiated talazoparib-triggered cytotoxicity in CML cells (Fig. 5). To further confirm the cytoprotective role of autophagy in talazoparib-induced cytotoxicity, ATG5, a core autophagy molecular in the formation of autophagy initiation, was knocked down. Immunoblot analysis showed that siRNA-ATG5 selectively decreased the protein level of ATG5 in CML P#1 and P#2 cells when compared with the non-target control (Fig. 6). After knockdown of ATG5 in talazoparib-treated CML cells, talazoparib-induced cytotoxicity was significantly enhanced (Fig. 6). Therefore, our results demonstrated that talazoparib-induced autophagy played a cytoprotective role in CML cells. Autophagy inhibition could significantly potentiate the anti-tumor effect of PARP inhibitor talazoparib in CML.
Talazoparib combined with autophagy inhibitor induced synergetic anti-tumor effect in CML PDX model
To confirm the therapeutic effect of talazoparib in combination with autophagy inhibitor for pediatric CML treatment, PDX model was established. In Fig. 7, tumor volume showed no remarkable difference among vehicle control group and chloroquine groups. However, tumor volume reduced significantly from day 6 in talazoparib and chloroquine co-treated group (P < 0.01). After treatment with talazoparib and/or chloroquine for 21 days, mean tumor weight of vehicle, chloroquine, talazoparib, talazoparib in combination with chloroquine were 665.4 ± 55.85 mg, 678 ± 44.75 mg, 430 ± 57.56 mg, 188.8 ± 35.06 mg. These data showed that talazoparib could inhibit CML growth in vivo. When CML-bearing mice were administrated with talazoparib and chloroquine, the anti-tumor effect was significantly increased (Fig. 7). Thus, talazoparib showed potent anti-CML effect in vivo, inhibition of autophagy by chloroquine potentiated the anti-CML effect of talazoparib.
To date, PARP inhibitors such as olaparib, rucaparib, niraparib and talazoparib have been approved by FDA to treat BRCA-mutated ovarian and breast cancers (Franzese et al. 2019). Clinical application of those PARP inhibitors offered beneficial effects to patients by its unique ability to selectively kill the cancer cells with homologous recombination deficiency (Karantza-Wadsworth et al. 2007). Talazoparib is an oral PARP inhibitor and was newly approved in the USA for the treatment of locally advanced and metastatic HER2-negative breast cancer. Talazoparib also underwent the development for use in metastatic castration-resistant prostate cancer and early triple negative breast cancer (Hoy 2018). However, whether PARP inhibitor talazoparib could elicit cytotoxicity in CML cells was still unclear. In current study, it was the first report to evaluate the anti-tumor effect of talazoparib in CML. Our results showed that talazoparib treatment induced a concentration-dependent cytotoxicity in primary CML cells and reduced the tumor growth in PDX model.
Although accumulating evidences show that PARP inhibitor has potent anti-tumor effect in some malignancies, strategies to enhance the effect are still desperately needed (Scott et al. 2015). To further enhance the anti-tumor effect of talazoparib in CML, we examined the status of autophagy in talazoparib-treated CML cells. Although autophagy showed as a “double-edged sword” in carcinogenesis, increasing literatures indicated the cyto-protective function of autophagy in tumor treatment and autophagy has been regarded as a potential target for synergetic anti-tumor therapeutics (He and Klionsky 2009). Literatures showed that targeting autophagy-related proteins LC3, ATG5, ATG7, SQSTM1, and Akt/mTOR (mammalian target of rapamycin) pathway could regulate autophagy initiation in cancer cells (Wen et al. 2018). In the current study, we reported that autophagy was markedly triggered by talazoparib in CML cells, which was confirmed by the accumulation of autophagosomes, decrease of SQSTM1 and up-regulation of LC3-II.
Assessment of the function of autophagy in PARP inhibitor-based tumor treatment was still rare. To address this point, pharmaceutical inhibitor and siRNA were employed to block talazoparib-induced autophagy in CML cells. Though autophagy played a crucial role in both cell death and cell survival (Washington et al. 2015), our results showed that inhibition of autophagy significantly increased talazoparib-triggered cytotoxicity in CML cells, indicating autophagy as a cyto-protective mechanism in talazoparib treatment in vitro. In CML PDX model, we investigated the anti-tumor effect of talazoparib in combination with chloroquine and found that autophagy inhibitor chloroquine significantly potentiated the anti-tumor effect of talazoparib. Taken together, our results demonstrated that PARP could be a promising target for CML treatment and highlighted the synergetic anti-tumor effects of co-targeting PARP and autophagy, providing novel insights for CML treatment.
Availability of data and materials
Please contact the author for data request.
poly (ADP-ribose) polymerases
chronic myeloid leukemia
non-silencing scrambled control
microtubule-associated protein 1 light chain3
mammalian target of rapamycin
Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785–3790. https://doi.org/10.1200/JCO.2008.16.0812
Chen Q, Ye L, Fan J, Zhang X, Wang H, Liao S, Song P, Wang Z, Wang S, Li Y, Luan J, Wang Y, Chen W, Zai W, Yang P, Cao Z, Ju D (2017) Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase in vitro and in vivo. Oncotarget 8:91052–91066. https://doi.org/10.18632/oncotarget.19409
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. https://doi.org/10.1038/nature03445
Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW (2018) Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. J Immunother Cancer 6:133. https://doi.org/10.1186/s40425-018-0445-4
Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M (2019) PARP inhibitors in ovarian cancer. Cancer Treat Rev 73:1–9. https://doi.org/10.1016/j.ctrv.2018.12.002
Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW (2018) Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res 6:1260–1273. https://doi.org/10.1158/2326-6066.CIR-17-0537
He C, Klionsky DJ (2009) Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43:67–93. https://doi.org/10.1146/annurev-genet-102808-114910
Hoy SM (2018) Talazoparib: first global approval. Drugs 78:1939–1946. https://doi.org/10.1007/s40265-018-1026-z
Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd (2018) Targeting tissue factor for immunotherapy of triple-negative breast cancer using a second-generation ICON. Cancer Immunol Res 6:671–684. https://doi.org/10.1158/2326-6066.CIR-17-0343
Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D’Andrea AD, Curtin NJ, Wong KK, Shapiro GI (2011) Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 17:875–882. https://doi.org/10.1038/nm.2377
Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, White E (2007) Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 21:1621–1635. https://doi.org/10.1101/gad.1565707
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marte J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL (2018) Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 6:141. https://doi.org/10.1186/s40425-018-0463-2
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20:e15–e28. https://doi.org/10.1016/S1470-2045(18)30786-1
Liu EY, Xu N, O’Prey J, Lao LY, Joshi S, Long JS, O’Prey M, Croft DR, Beaumatin F, Baudot AD, Mrschtik M, Rosenfeldt M, Zhang Y, Gillespie DA, Ryan KM (2015) Loss of autophagy causes a synthetic lethal deficiency in DNA repair. Proc Natl Acad Sci USA 112:773–778. https://doi.org/10.1073/pnas.1409563112
Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293–301. https://doi.org/10.1038/nrc2812
Samaniego R, Gutierrez-Gonzalez A, Gutierrez-Seijo A, Sanchez-Gregorio S, Garcia-Gimenez J, Mercader E, Marquez-Rodas I, Aviles JA, Relloso M, Sanchez-Mateos P (2018) CCL20 Expression by tumor-associated macrophages predicts progression of human primary cutaneous melanoma. Cancer Immunol Res. https://doi.org/10.1158/2326-6066.cir-17-0198
Scott CL, Swisher EM, Kaufmann SH (2015) Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 33:1397–1406. https://doi.org/10.1200/JCO.2014.58.8848
Shen W, Zhang X, Fu X, Fan J, Luan J, Cao Z, Yang P, Xu Z, Ju D (2017) A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor. Cell Death Dis 8:e2720. https://doi.org/10.1038/cddis.2017.137
Shenoy GN, Loyall J, Maguire O, Iyer V, Kelleher RJ Jr, Minderman H, Wallace PK, Odunsi K, Balu-Iyer SV, Bankert RB (2018) Exosomes associated with human ovarian tumors harbor a reversible checkpoint of T-cell responses. Cancer Immunol Res 6:236–247. https://doi.org/10.1158/2326-6066.CIR-17-0113
Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB (2017) Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aal5148
Tang CH, Chang S, Hashimoto A, Chen YJ, Kang CW, Mato AR, Del Valle JR, Gabrilovich DI, Hu CC (2018) Secretory IgM exacerbates tumor progression by inducing accumulations of MDSCs in mice. Cancer Immunol Res 6:696–710. https://doi.org/10.1158/2326-6066.CIR-17-0582
Ureshino H, Shindo T, Kojima H, Kusunoki Y, Miyazaki Y, Tanaka H, Saji H, Kawaguchi A, Kimura S (2018) Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res 6:745–754. https://doi.org/10.1158/2326-6066.CIR-17-0462
Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC Jr, Lu Z (2015) ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis 6:e1836. https://doi.org/10.1038/cddis.2015.208
Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang Y, Zhao J, Chen Y, Zhang T, Huang F, Pan N, Zhang J, Fox BA, Hu HM, Wang LX (2018) Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. J Immunother Cancer 6:151. https://doi.org/10.1186/s40425-018-0452-5
Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, Luan J, Wang Z, Song P, Chen Q, Tian W, Ju D (2017) Targeting CD47 and autophagy elicited enhanced antitumor effects in non-small cell lung cancer. Cancer Immunol Res 5:363–375. https://doi.org/10.1158/2326-6066.CIR-16-0398
Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, Li Y, Wang Y, Nan Y, Luo M, Li S, Tian W, Ju D (2018a) Disrupting CD47-SIRPalpha axis alone or combined with autophagy depletion for the therapy of glioblastoma. Carcinogenesis 39:689–699. https://doi.org/10.1093/carcin/bgy041
Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, Wang Y, Liang Y, Li S, Tian W, Ju D (2018b) Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma. Appl Microbiol Biotechnol 102:6503–6513. https://doi.org/10.1007/s00253-018-9069-3
Zimmer AS, Gillard M, Lipkowitz S, Lee JM (2018) Update on PARP inhibitors in breast cancer. Curr Treat Options Oncol 19:21. https://doi.org/10.1007/s11864-018-0540-2
Ethics approval and consent to participate
The study was conducted according to the Declaration of Helsinki and approved by Medical Ethical Committee of the Second Affiliated Hospital of Zhengzhou University. Informed consent was obtained from all patients.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Liu, Y., Song, H., Song, H. et al. Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia. AMB Expr 9, 108 (2019). https://doi.org/10.1186/s13568-019-0836-z
- Pediatric chronic myeloid leukemia